



## News Release

### **Suven's Income at Rs. 1377 Mn; PAT at Rs. 326 Mn for the 1st quarter ended June 2016**

**HYDERABAD, INDIA (10 Aug' 2016)** – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS) today announced its un-audited financial results for the quarter ending 30th June 2016. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 10th Aug 2015 at Hyderabad.

#### **Financial Highlights for the 1st Quarter ended June' 2016 vs 1st Qtr ended June 2015**

Growth in revenue Rs 1377 Mn vs. Rs 1060 Mn - Up by 29.54%

Growth in PAT Rs 326 Mn vs. Rs 206 Mn - Up by 58.12%

Growth in EBIDTA Rs 479 Mn vs. Rs 307 Mn - Up by 56.34%

#### **Financial Highlights for the 1st Quarter ended June' 2016: (QoQ)**

Growth in revenue Rs 1377 Mn vs. Rs 1694 Mn - Down by 20.81%

Growth in PAT Rs 326 Mn vs. Rs 372 Mn - Down by 12.38%

Growth in EBIDTA Rs 479 Mn vs. Rs 524 Mn - Down by 8.56%

Suven's thrust on innovative R&D in Drug Discovery continues with a spending of Rs 147 Mn (10.67% on revenue) for the quarter ended 30th June 2016.

**For more information on Suven please visit our Web site at <http://www.suven.com>**

#### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;***